Clinical Trial Update: Efficacy&Safety of ALTB-168 in Patients With Moderate to Severe Active,Anti-TNF Alpha and/or Anti-integrin Refractory UC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ALTB-168 for moderate to severe ulcerative colitis that is refractory to anti-TNF or anti-integrin therapy; study terminated with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• ALTB-168

Snippet

Sponsor: AltruBio Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2023-07-06